Roferon A (recombinant interferon alfa-2a) / Roche - LARVOL DELTA

Airway anaerobic commensals are associated with distinct pro-inflammatory endotypes in individuals with chronic pulmonary aspergillosis (ERS 2026) - "Conclusion Airway dysbiosis with presence of oral commensal anaerobic bacteria represent distinct patient clusters which correlate with pro-inflammatory cytokines in CPA. Further analysis is ongoing to understand impact on disease progression, severity and therapeutic strategy."

Clinical • Infectious Disease • Respiratory Diseases • IFNA1 • IL1B

Mortality, Thrombotic, Hemorrhagic, and Cardiovascular Outcomes With JAK1/JAK2/IRAK1 Inhibitors Versus Conventional Cytoreductive Therapy in Myeloproliferative Neoplasms: A Real-World Propensity-Matched Analysis (SOHO 2026) - "Patients: Adults aged 18–75 years with MPN-spectrum diagnoses (polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic myeloproliferative disease, CML, MDS; ICD-10 codes D45, D46, D47.1, D47.3, D47.4, D47.Z9, C92.1) on/after January 1, 2010, initiating a JAK1/JAK2/IRAK1 inhibitor (ruxolitinib, fedratinib, pacritinib, momelotinib; n = 4251) or non-JAK cytoreductive agent (hydroxyurea, anagrelide, interferon alfa-2a/2b; n = 14448) within 3 months of diagnosis... JAK1/JAK2/IRAK1 inhibitor therapy was associated with markedly higher 3-year mortality, hospitalization, major bleeding, VTE, and heart failure compared with non-JAK cytoreductive therapy. Because JAK inhibitors are preferentially used in higher-risk MPN phenotypes imperfectly captured by ICD coding, residual confounding by unmeasured disease severity likely contributes. Prospective comparative effectiveness studies with granular severity adjustment are needed."

Clinical • Real-world • Real-world evidence • Chronic Myeloid Leukemia • Essential Thrombocythemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • IRAK1 • JAK1 • JAK2

PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY (EHA 2023) - P1/2 | "Preliminary results from Arm 4 of the MANIFEST study suggest potential clinical benefit with PELA monotherapy in pts with HR ET refractory or intolerant to HU as supported by hematologic responses and symptom improvement. Safety data suggest a tolerable and manageable safety profile. Mutation data and other pharmacodynamic analyses indicate potential biomarker changes after PELA monotherapy."

Clinical • Monotherapy • Cardiovascular • Essential Thrombocythemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Thrombocytopenia • Thrombocytosis • BDNF • CALR • CXCL8 • DKK1 • JAK2 • MMP1 • MMP9 • TIMP3

Evaluation of a Virtual Multicentric Interdisciplinary Tumor Board for Cutaneous Lymphoma (BAD 2026) - "The five most frequently recommended therapies were total-skin electron beam therapy (10.9%), allogeneic haematopoietic stem cell transplantation (9.9%), systemic treatment with brentuximab vedotin (8.3%) or interferon alfa-2a (7.9%), and extracorporeal photopheresis (7.6%)...Moreover, extended diagnostic procedures and additional imaging were frequently advised. Data derived from evaluation forms are currently being processed and the data will be presented at the conference."

Clinical • Cutaneous T-cell Lymphoma • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Presurgical immune biomarkers associated with pain intensity and pain interference recovery after total knee arthroplasty: findings from the PRIME-KNEE study. (PubMed, medRxiv) - "Protein-protein interaction analyses and topology motifs suggest a centralized network with higher-than-expected connectivity, involving IL-5, IL-7, IL-8, MIP-1β, and IFN-α2a, among others. This study proposes rigorous yet feasible approaches to expedite pain biomarker research and introduces presurgical biomarkers to consider in future TKA-CPSP biosignature derivation."

Biomarker • Journal • Cytomegalovirus Infection • Hematological Malignancies • Leukemia • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Orthopedics • Pain • CCL4 • CXCL8 • IFNA1 • IL5 • IL7 • LBP • LIF

USE OF BEVACIZUMAB IN AGGRESSIVE PEDIATRIC LARYNGEAL PAPILLOMATOSIS: A CASE REPORT DEMONSTRATING REDUCED SURGICAL BURDEN AND CONTRIBUTING TO THE LIMITED LITERATURE (ESPID 2026) - "Owing to persistent symptoms, she underwent 14 surgical procedures, including intralesional cidofovir administration during 4 operations...Because an opportunistic fungal infection could not be excluded, voriconazole therapy was started...In this case, bevacizumab appeared to reduce the need for repeated surgical interventions. This case may serve as a valuable example suggesting that bevacizumab can help decrease surgical burden and maintain clinical stability in aggressive pediatric disease until more definitive treatment options become available."

Case report • Clinical • Infectious Disease

Reply to comments on Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanoma. (PubMed, Am J Ophthalmol) - No abstract available

Journal • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor

Comment on "Interferon Alpha-2a as Treatment for Primary Acquired Melanosis With Atypia and for Primary Acquired Melanosis With Atypia Surrounding Conjunctival Melanoma". (PubMed, Am J Ophthalmol) - No abstract available

Journal • Eye Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor

Protein-Capturing Microgel-Integrated Microneedle Array Patches for Enhanced Tip-Loading, Storage Stability, and Transdermal Delivery of Recombinant Proteins. (PubMed, Small) - "Transdermal delivery of CpG-adjuvanted RBD using MI-MAP elicits a more rapid neutralizing antibody response and germinal center B-cell proliferation in mice than HA-MAP and subcutaneous injection, without causing any severe inflammation. This study presents a potential strategy for improving tip-loading and storage stability of recombinant proteins within microneedle structures."

Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases

EFFECTS OF TREATMENT WITH TEMSIROLIMUS VERSUS INTERFERON ALPHA ON SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA - SINGLE-CENTER REAL-WORLD EXPERIENCE. (PubMed, Acta Clin Croat) - "In conclusion, temsirolimus therapy had a significantly positive effect on survival in patients with mRCC. Patients treated with temsirolimus showed significantly longer median survival and median PFS compared to patients treated with IFN-alpha."

Clinical • Journal • Real-world evidence • Retrospective data • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urology • IFNA1

Comparative Real-World Effectiveness of Immunomodulatory Therapies for Prevention of Uveitis Relapse in Behçet's Disease. (PubMed, Arthritis Rheumatol) - "In Behçet's disease, interferon alfa-2a was associated with a reduction in uveitis relapse compared with cyclosporine, while adalimumab demonstrated a stronger association with reduced relapse than interferon alfa-2a."

Journal • Real-world evidence • Ocular Inflammation • Ophthalmology • Rare Diseases • Uveitis

Efficacy of Topical Chemotherapy in Ocular Adnexal Sebaceous Carcinoma. (PubMed, Ophthalmic Plast Reconstr Surg) - "Topical chemotherapy agents were utilized via monotherapy or in combination and included mitomycin C (MMC) 0.02% or 0.04% (8 cases), 5-fluorouracil 1% (3 cases), and interferon alpha-2a 1 million units/ml (2 cases)...Both patients who achieved local conjunctival tumor control were treated with MMC for at least 3 total weeks of therapy, although residual disease within the eyelid was still identifiable on pathology following surgical resection. Topical MMC may be used in the neoadjuvant setting for OaSC with pagetoid spread; however, additional studies are needed to determine the optimal dosing and treatment duration to minimize adverse effects and reduce ocular surface comorbidity."

Journal • Eye Cancer • Oncology

Successful treatment of depressed esophageal squamous papilloma with interferon- alpha 2a: A case report. (PubMed, World J Clin Cases) - "This paper reports the first successful clinical case of using the human IFNα2a for the treatment of ESP with a depressed endoscopic appearance. However, the efficacy of interferon treatment requires to validation in a large number of subsequent cases."

Journal • Esophageal Cancer • Oncology • IFNA1

Predicting response to infliximab and interferon-α in Behçet's syndrome: An exploratory analysis from the BIO-BEHÇET'S randomized controlled trial. (PubMed, Rheumatol Immunol Res) - "BIO-BEHÇET'S suggests there is potential for a novel metabolomic biomarker that can identify response to infliximab in patients with Behçet's Syndrome. Further work will characterize the appropriate metabolite (s) from existing samples to inform future prospective trials to study this in more detail clinically."

Clinical • Journal • Immunology • Rare Diseases • IFNL3

Therapeutic difficulties in the treatment of a girl with primary hypoparathyroidism (ESPE-ESE 2025) - "Although primary hypoparathyroidism is a rare endocrinopathy in children, it often causes therapeutic difficulties, as there is no standard hormone replacement therapy."

Cardiovascular • CNS Disorders • Endocrine Disorders • Epilepsy • Hypoparathyroidism • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Metabolic Disorders • Nephrology • Pediatrics • Pneumonia • Primary Immunodeficiency • Renal Disease • Respiratory Diseases • Systemic Lupus Erythematosus • IFNA1 • IL17A • IL22

Prognostic Factors of Treatment Failure with First-Line Corticosteroid-Sparing Agents in Patients with Birdshot Chorioretinopathy: A Retrospective Study. (PubMed, Ocul Immunol Inflamm) - "First-line treatment consisted in oral corticosteroids (prednisone) and mycophenolate mofetil (MMF) or interferon alpha-2a (IFN). Second-line treatment consisted in biologics, i.e. anti-TNFα or tocilizumab (TCZ)...Among 11 patients treated sequentially with MMF, anti-TNFα and TCZ, mean prednisone dose significantly decreased with anti-TNFα compared to MMF (13.2 vs 21.9 mg/day, p = 0.002), TCZ compared to MMF (5.7 vs 21.9, p < 0.001) and TCZ compared to anti-TNFα (5.7 vs 13.2, p = 0.001). At baseline, clinical papillitis, angiographic papillary leakage, RNFL thickness and mean deviation could be prognostic factors of treatment failure with first-line corticosteroid-sparing agents in patients with BCR."

Biomarker • Journal • Retrospective data • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis

Comment on: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis: reply. (PubMed, Rheumatology (Oxford)) - No abstract available

Journal • Immunology • Scleroderma • Systemic Sclerosis

Comment On: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis. (PubMed, Rheumatology (Oxford)) - No abstract available

Journal • Immunology • Scleroderma • Systemic Sclerosis

Idiopathic Photoreceptoritis: An Unusual Variant of Outer Retinopathy. (PubMed, Ocul Immunol Inflamm) - "Despite oral valaciclovir, the disease progressed rapidly, prompting referral to a tertiary care center...Given the temporal association with the herpetic infection and the sight-threatening progression, treatment was escalated to intravenous acyclovir and subsequently foscarnet for 2 weeks, which slowed down disease progression...The disease was stabilized with antiviral therapy, while structural recovery of the photoreceptors was achieved through anti-inflammatory and immunosuppressive treatments. This report underscores the importance of a multidisciplinary approach to managing atypical retinal inflammatory disorders."

Journal • Infectious Disease • Inflammation • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis

Successful management of large conjunctival squamous cell carcinoma with excisional biopsy, topical interferon, and amniotic membrane grafting: A case report. (PubMed, Int J Surg Case Rep) - "A multidisciplinary treatment strategy can effectively manage advanced conjunctival SCC, as seen in this case, where no recurrence occurred after one year of follow-up. Early detection and comprehensive care are essential for positive outcomes."

Journal • Oncology • Ophthalmology • Squamous Cell Carcinoma

Recurrence rate of corneal squamous cell carcinoma in dogs undergoing superficial keratectomy surgery. (PubMed, Open Vet J) - "Dogs with chronic corneal inflammatory conditions, particularly brachycephalic breeds, are at higher risk for developing cSCC. Corneal SCC should be suspected in middle-aged brachycephalic dogs presenting with proliferative, raised, or hyperaemic corneal lesions."

Journal • Retrospective data • Keratitis • Ocular Inflammation • Oncology • Squamous Cell Carcinoma

Successful checkpoint inhibition in a patient with metastatic melanoma and advanced Sézary syndrome (ADO 2024) - "These include PUVA, MTX, Roferon, mogamulizumab, brentuximab, bexarotene, all of which were combined with extracorporeal photopheresis (ECP) that had been performed for several years...The adjuvant therapy with pembrolizumab that had already been initiated was not continued after the decision of the interdisciplinary lymphoma board due to insufficient data and the fear of hyperprogression of the SS after one cycle...After consultation in the interdisciplinary tumor board decision, the patient received combined immunotherapy with ipilimumab and nivolumab (3 and 1m kg body weight q3w, respectively) as well as stereotactic radiation (ED/GD 20Gy). Mogamulizumab was stopped and ECP continued. We report on the further course, the encouraging response and the overall good tolerability of this therapy both with regard to the metastatic melanoma and the SS."

Checkpoint inhibition • Clinical • Metastases • Cutaneous Melanoma • Cutaneous T-cell Lymphoma • Dermatopathology • Melanoma • Oncology • Sezary Syndrome • Solid Tumor • CD4 • CD8

Cyclosporin A as an adjunct may enhance the therapeutic effect of interferon alpha-2a in patients with refractory Behcet's uveitis: a retrospective cohort study. (PubMed, Ther Adv Chronic Dis) - "Overall, the frequency of uveitis relapse and the dose of oral prednisolone were significantly reduced in both groups after treatment (all p < 0.0001)...IFN-α2a treatment is a promising option for patients with refractory BU. Our results showed that cyclosporin A as an adjunct could enhance the therapeutic effect of IFN-α2a."

Journal • Retrospective data • Immunology • Ocular Inflammation • Ophthalmology • Rare Diseases • Uveitis • IFNA1

Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis. (PubMed, Rheumatology (Oxford)) - "Using serum determinations, the activation of the T1 IFN pathway showed strong correlations with inflammatory mediators and associations with clinical manifestations, especially skin fibrosis and ILD in SSc patients. However, activated IFN pathway was not predictive of ILD progression."

Journal • Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • CCL19 • CCL8 • CXCL10 • CXCL11 • IFNA1

A puzzling case of Angiolymphoid Hyperplasia with Eosinophilia: diagnosis and management challenges (EADV 2024) - "Other treatment options are pulsed-dye laser, CO2 laser, cryosurgery, systemic or intralesional corticotherapy, imiquimod, tacrolimus, isotretinoin, interferon alfa2a, anti-IL-5 antibodies, or dupilumab. Oral propranolol might be of use in selected patients. ALHE is a rare disease but it has characteristic histopathological findings that can help the diagnosis. There are a large variety of proposed treatments but not enough data on most of them. Surgical excision is the treatment of choice in forms with fewer lesions."

Clinical • Angiosarcoma • Eosinophilia • Hematological Malignancies • Hepatology • Lymphoma • Oncology • Rare Diseases • Sarcoma • Solid Tumor • IL5